Primary progressive aphasia

A tale of two syndromes and the rest

S.A. Sajjadi, MRCP
K. Patterson, FMedSci
R.J. Arnold
P.C. Watson, PhD
P.J. Nestor, FRACP,
PhD

Correspondence & reprint
requests to Dr. Nestor:
pjn23@hermes.cam.ac.uk

ABSTRACT

Objective: Primary progressive aphasia (PPA) has been proposed to comprise 3 discrete clinical subtypes: semantic, agrammatic/nonfluent, and logopenic. Recent consensus recommendations suggest a diagnostic framework based primarily on clinical and neuropsychological findings to classify these variants. Our objective was to evaluate the extent to which patients with PPA would conform to the proposed tripartite system and whether the clustering pattern of elements of the linguistic profile suggests discrete clinical syndromes.

Methods: A total of 46 patients with PPA were prospectively recruited to the Cambridge Longitudinal Study of PPA. Sufficient data were collected to assess all consensus-proposed diagnostic domains. By comparing patients' performances against those of 30 age- and education-matched healthy volunteers, z scores were calculated, and values of 1.5 SDs outside control participants' means were considered abnormal. Raw test scores were used to undertake a principal factor analysis to identify the clustering pattern of individual measures.

Results: Of the patients, 28.3%, 26.1%, and 4.3% fitted semantic, nonfluent/agrammatic, and logopenic categories respectively, and 41.3% did not fulfill the diagnostic recommendations for any of the 3 proposed variants. There was no significant between-group difference in age, education, or disease duration. Furthermore, the outcome of the factor analysis was in keeping with discrete semantic and nonfluent/agrammatic syndromes but did not support a logopenic variant.

Conclusion: Taken together, the results of this prospective data-driven study suggest that although a substantial proportion of patients with PPA have neither the semantic nor the nonfluent variants, they do not necessarily conform to a discrete logopenic variant. *Neurology*® 2012;78:1670-1677

GLOSSARY

lvPPA = logopenic variant of primary progressive aphasia; **nfvPPA** = nonfluent/agrammatic variant of primary progressive aphasia; **PPA** = primary progressive aphasia; **svPPA** = semantic variant of primary progressive aphasia.

Primary progressive aphasia (PPA) is a collective term for a group of clinically and pathologically heterogeneous disorders in which a neurodegenerative disease presents with language impairment as the most salient feature.¹ The current clinical formulation posits 3 variants: semantic variant (svPPA, also known as semantic dementia), nonfluent/agrammatic variant (nfvPPA), and logopenic variant (lvPPA).²⁻⁴ Recently, diagnostic recommendations (table 1) have been proposed to enable identification of these 3 most commonly reported clinical presentations of PPA.⁵ It remains unclear, however, whether there are only 3 definable syndromes or indeed whether all 3 of these proposed categories are sufficiently discrete and consistent to justify them being delineated as specific syndromes.

A particular advance with these proposed recommendations was the stipulation of specific types of tests to assess certain language features. Many of the recommendations, however, still rely on evaluating connected speech. Despite publication of a few formal analyses,^{6,7} connected speech is typically not quantified and, hence, at risk of inconsistent evaluation or bias. The Cambridge Longitudinal Study of PPA was established for prospective evaluation of the phe-

Supplemental data at
www.neurology.org

Supplemental Data

From the Neurology Unit (S.A.S., K.P., R.J.A., P.J.N.), University of Cambridge, Herchel Smith Building for Brain and Mind Sciences, Cambridge, UK; and Methods Group (P.C.W.), MRC Cognition and Brain Sciences, Cambridge, UK.

Study funding: Supported by the Donald Forrester Trust research grant to S.A.S. and NIHR Cambridge Biomedical Research Centre Go to Neurology.org for full disclosures. Disclosures deemed relevant by the authors, if any, are provided at the end of this article.

Table 1 Proposed recommendations for clinical diagnosis of PPA variants

	nfvPPA: At least one core and two-thirds of other features	svPPA: Both core and three-fourths of other features	lvPPA: Both core and three-fourths of other features
Core features	Agrammatism in language production	Impaired confrontation naming	Impaired single word retrieval in speech and naming
	Effortful halting speech with inconsistent speech sound errors and distortions	Impaired single-word comprehension	Impaired repetition of sentences and phrases
Other diagnostic features	Impaired comprehension of syntactically complex sentences	Impaired object knowledge	Phonologic errors in speech and naming
	Spared single word comprehension	Surface dyslexia or dysgraphia	Spared single word comprehension and object knowledge
	Spared object knowledge	Spared repetition	Spared motor speech
		Spared speech production	Absence of frank agrammatism

Abbreviations: lvPPA = logopenic variant of primary progressive aphasia; nfvPPA = nonfluent/agrammatic variant of primary progressive aphasia; svPPA = semantic variant of primary progressive aphasia.

nomenclology of PPA, using a detailed neuropsychological battery and formal analysis of connected speech. In this study, 46 consecutively recruited patients were tested to examine the extent to which patients would conform to the proposed tripartite system. In addition, a purely data-driven analysis was undertaken to identify the elements of linguistic impairment that cluster together, thus using empirical evidence to test for the existence of discrete syndromic variants.

METHODS **Participants.** A total of 46 patients with a clinical diagnosis of PPA were prospectively recruited over a 2 year period (2009–2011) from the memory clinics held at Addenbrooke's Hospital, University of Cambridge, UK. All patients met the basic criteria for PPA.⁵ Nondegenerative pathologies were excluded using MRI, except in 3 patients who had CT because MRI was contraindicated. Previous experience had shown that cognitive screening tests such as the Mini-Mental State Examination, for which responses often require speaking, could be misleading in assessment of functional abilities in patients with prominent language problems.^{8,9} We designed an informant-filled questionnaire on activities of daily living to assess patients' ability to cope with language-independent day-to-day activities. In addition, prospective participants were excluded if 1) English was not their first language (excluded 1 patient) or 2) their language was so impaired that they could not provide speech samples of the length and quality required for meaningful analysis (excluded 1 patient). Spouses/partners of patients were recruited as control subjects to be matched for general demographic factors, especially age and education. All were free of cognitive symptoms and neurologic or psychiatric illnesses and performed normally on Addenbrooke's Cognitive Examination—Revised.¹⁰

Standard protocol approvals, registrations, and patient consents. Written informed consent was obtained from the participants and, where appropriate, their next of kin. The study was approved by the regional ethics committee.

Neuropsychological battery. All subjects with PPA and control participants performed a similar set of general neuropsychological tests (table 2) and an extensive battery of language-specific tests that, along with the outcome of their connected speech analysis, were explicitly chosen to evaluate all consensus-proposed language markers. Connected speech was elicited in 2 ways: 1) by description of the picture (a busy domestic scene) from the Dutch version of the Comprehensive Aphasia Test¹¹ and 2) by semistructured interviews. To provide an objective measure of the patients' performance relative to that of healthy participants and to binarize the individual test scores to normal or abnormal, which was required for the first part of the analyses, standard scores were calculated. To examine the degree to which the patients could be classified using the recently proposed recommendations, their standard scores were used to assess the presence or absence of the diagnostic features for each of the 3 proposed variants. Inspired by criteria for minimal cognitive impairment,¹² a threshold of 1.5 SDs worse than the control participants' mean was set as the boundary of normal. Data were also analyzed using a 95% confidence interval (1.96 SDs) to see whether this stricter threshold would be more specific in assigning patients to syndromic groups. Raw scores were used for principal factor analysis.

Based on the consensus recommendations, the following language features were assessed: agrammatism in language production; motor speech impairment; comprehension of syntactically complex structures; basic syntactic production skills; word and sentence repetition; confrontation naming; single word comprehension; object knowledge; surface dyslexia; and frequency of phonologic errors in connected speech. Methodologic details for the assessment of these language markers are presented in appendix e-1 on the *Neurology*[®] Web site at www.neurology.org.

Statistical considerations. Predictive Analytics SoftWare (PASW) version 18 was used for statistical analysis of the data. *z* scores were calculated using the transform function in PASW. One-way analysis of variance or its nonparametric equivalent, the Kruskal-Wallis test, was used to compare the demographic and general neuropsychological markers in different groups of patients and control participants. A 2-tailed *p* value of 0.05 was considered significant. We also undertook principal factor analysis with orthogonal varimax rotation on the 14 speech features listed in table 3 to identify the clustering pattern of individual measures. Factors with eigenvalues over the Kaiser criterion of 1 were retained.¹³

Table 2 Frequency of syndromic variants and comparison of demographic and general neuropsychological markers

	nfvPPA	svPPA	lvPPA	Mixed PPA	Control	Omnibus significance: $p < 0.05$
No. (%)	12 (26.1)	13 (28.3)	2 (4.3)	19 (41.3)	30	
Demographic markers, mean (range)						
Age at test, y	68 (53–77)	68 (61–79)	71 (68–74)	70 (60–83)	67.5 (51–80)	NS
Disease duration, y	3.5 (2–5)	4.4 (2.5–7)	2 (1.5–2.5)	3.9 (2–7)	NA	NS
Education, y	13 (10–20)	14 (10–19)	11 (9–13)	11 (9–16)	12.8 (10–20)	NS
ADL-Q	0.73 (0–4)	1 (0–5)	0.5 (0–1)	1.3 (0–6)	NA	NS
General neuropsychological measures, mean (range)						
MMSE (30) ^a	24.6 (15–28)***	23 (18–27)***	25.5 (25–26)**	17.9 (10–28)***,b,c,d	29.2 (28–30)	< 0.001
ACE-R (100)	74.1 (44–89)***	52 (36–87)***,e	72.0 (68–76)***	46.5 (28–69)***,b,f,g	94.4 (88–99)	< 0.001
Forward digit span (8)	4.5 (3–7)***,c	6.3 (4–8)	5.1 (4–6)*,f	4.4 (3–8)***,h	6.7 (5–8)	< 0.001
Backward digit span (7)	3.7 (0–4)***	4.2 (3–7)	4.0 (3–5)*	3.0 (0–6)***,c	5.1 (3–8)	< 0.001
Letter fluency, words/min	5.3 (1–11)***	6.0 (1–11)***	6.5 (6–7)**	4.8 (1–11)***	14.4 (4–21)	< 0.001
VOSP (10) ⁱ	8.2 (4–10)*,f	9.8 (9–10)	7.5 (5–10)*	6.6 (2–10)**,f	9.3 (8–10)	< 0.001
Rey figure copy (36)	26.5 (2.5–36)***,f	33 (30–36)	20.5 (19–22)***,c	21.1 (0.5–35)***,h	34.6 (29–36)	< 0.001
Rey figure recall (36)	10.7 (0–23)**	10 (0–25)*	5.5 (2–9)**	7.4 (0–21)***	18.2 (0–29)	< 0.001
Trails-A (time), s ⁱ	104.5 (47–394)***,f	49.2 (21–98)	93 (69–117)**	106.6 (48–445)***,f	37.6 (22–62)	< 0.001

Abbreviations: ACE-R = Addenbrooke's Cognitive Examination–Revised; ADL-Q = activities of daily living questionnaire; lvPPA = logopenic variant of PPA; MMSE = Mini-Mental State Examination; NA = not applicable; nfvPPA = nonfluent/agrammatic variant of PPA; NS = nonsignificant; svPPA = semantic variant of PPA; VOSP = Visual Object and Perception Battery (cube analysis).

* $p < 0.05$ compared with the control population.

** $p < 0.01$ compared with the control population.

*** $p < 0.001$ compared with the control population.

^a Numbers in parentheses indicate the maximum score for each test.

^b $p < 0.001$ compared with nfvPPA.

^c $p < 0.01$ compared with svPPA.

^d $p < 0.001$ compared with lvPPA.

^e $p < 0.01$ compared with nfvPPA.

^f $p < 0.05$ compared with svPPA.

^g $p < 0.01$ compared with lvPPA.

^h $p < 0.001$ compared with svPPA.

ⁱ Nonparametric test.

RESULTS Assessment of the proposed recommendations.

Every patient was assessed against the diagnostic recommendations for each of the 3 proposed variants. With a z score threshold of 1.5, the score for none of the patients was too mild to meet the minimum diagnostic criteria for one of the syndromic variants. The frequencies of the syndromic variants are summarized in table 2 along with their demographic and general neuropsychological features.

Of the patients, 27 (59%) fitted 1 of the 3 categories, but 19 patients (41%) either fulfilled the diagnostic criteria for more than one variant or were too

impaired to fulfill the criteria for any variant (see table e-1 for an example for one patient). These latter 19 patients were labeled mixed. Repeating this procedure using the more stringent threshold of ≥ 1.96 SDs from the control mean led to a change in syndromic classification for only one patient, from nonfluent/agrammatic to mild/impaired on a single measure but did not affect the mixed group membership. Table 4 provides the neuropsychological and speech data for every patient in the mixed group. There was no statistically significant difference between the 4 patient groups (svPPA, nfvPPA, lvPPA,

Table 3 Thresholded factor loadings (≥ 0.4) of individual markers in the factor solution

	Factor			
	1	2	3	4
Point (subsection of repeat and point test)	0.911			
Camel & Cactus Test	0.844			
64-item Naming	0.926			
Irregular word reading	0.762			
SECT (orally presented)		0.839		
MAST (active sentences)		0.517		
Sentence repetition		0.872		
Apraxia of speech		0.710		
Complex unit frequency			0.773	
Mean unit length		0.435	0.623	
Speech rate			0.634	
Hesitation markers			-0.450	
Phonologic errors				-0.732
Grammatical errors				

Abbreviations: MAST = make a sentence test; SECT = sentence comprehension test.

and mixed PPA) and control participants in terms of their demographic markers.

Principal factor analysis. The Keiser-Myer-Olkin measure verified the sampling adequacy for the analysis (Keiser-Myer-Olkin = 0.68, significance < 0.001), and the rotation converged in 6 iterations. The correlation matrix confirmed satisfactory correlation coefficients for all but the grammatical error score in connected speech, which was not significantly correlated with any of the other markers. Four factors with eigenvalues more than 1 accounted for 64% of the variance in the data. Examination of the Scree plot (figure) revealed a large step down in eigenvalues from factor 2 to factor 3. The first 2 factors accounted for 42% of the variance. Table 3 shows thresholded factor loadings of individual markers in the factor solution (for an unthresholded version of the table, see table e-2). Scrutiny of the rotated factor matrix indicated that factor 1 clustered semantic measures, factor 2 clustered measures of grammatical competence, sentence repetition, apraxia of speech and, with a weaker factor loading, mean length of utterance, and factor 3 clustered a number of connected speech markers. The fourth factor comprised only one measure (phonologic errors).

DISCUSSION Publication of the recommendations for classification of PPA has been a necessary first step toward development of an empirical and unbiased categorization of the patients to clinically meaningful groups. Application of the recommendations to prospective cohorts such as this one provides an opportunity for evolution of these recommendations.

By applying the proposed measures for delineating the syndromic variants of PPA to this consecutively recruited cohort of 46 cases, 26.1% fulfilled the criteria for nfvPPA and 28.3% for svPPA but only 4.3% for lvPPA. A substantial 41.3% could only be classified as mixed PPA in that their deficits either extended beyond a single syndromic variant domain (i.e., they violated the stipulation that for a given syndromic variant a certain feature had to be spared) or they met the criteria for more than one variant. The possibility that this large group of mixed cases might be attributable to a longer duration of disease was not supported by the demographic data: the mixed group had disease duration similar to that of the other groups. The patients with mixed PPA fared worse on general neuropsychological measures at a group level, but this observation should be interpreted with caution. Because their aphasia was also more diffuse, it may be that it has a more pervasive effect on general cognition as has been noted previously.^{8,14} It is important to highlight the possibility that performance on general cognitive measures was not systematically worse in all patients with mixed aphasia. Finally, it is worth noting that, from a pathologic point of view, such performance is not in itself evidence for a different pathologic grouping: in a previous study, nonlinguistic measures were inconsistently affected across pathologic substrates for PPA.¹⁵

Of note, the authors of the recent recommendations speculated that there may be instances in which language impairment is so mild that the patient fails to meet any criteria (i.e., by only being impaired on a single measure)^{5,16}; in this prospective sample, no patients fell into this category with a cutoff of 1.5 SDs and only one patient at a threshold of 1.96.

One could argue that strict application of cutoff scores to define the impairments that were set out in the consensus article might be too rigid to recognize the nuances of the proposed syndromic categories. It is therefore notable that principle axis factoring, involving no prior assumptions as to the existence of predetermined syndromic variants, yielded a pattern identical to the application of the consensus recommendations: 2 clear syndromes and a residual miscellany. The first factor clustered single word comprehension, nonverbal associative knowledge, picture naming, and irregular word reading. All of

Table 4 Individual standard and percentage corrected scores for neuropsychological and speech measures in the mixed group^a

Domain ^a and test											
Patient	Object knowledge: CCT, %	Single word comp: Point, %	Reading: Irregular word reading, %	Confrontation naming: 64-item naming, %	Repetition: Sentence repetition, %	Sentence comp: SECT, %	Grammar		Motor speech		
							MAST-Active sentence, %	Agrammatism, composite z-scores	Phonologic errors, z-score	Hesitation markers, z-score	Apraxia of speech
1	44 ^b	80 ^c	40 ^b	81 ^c	25 ^b	40 ^b	67 ^b	2.61 ^b	3.9 ^b	1.8 ^b	+
2	73 ^b	60 ^b	100	70 ^b	50 ^b	44 ^b	100	2.05 ^b	6.4 ^b	0.5	+
3	0 ^b	20 ^b	60 ^b	61 ^b	83 ^b	0 ^b	0 ^b	2.32 ^b	10.1 ^b	1.3	–
4	30 ^b	40 ^b	100	48 ^b	17 ^b	0 ^b	0 ^b	3.20 ^b	10.3 ^b	–1.0	+
5	62 ^b	70 ^b	60 ^b	2 ^b	67 ^b	20 ^b	0 ^b	0.49	4.5 ^b	4.9 ^b	+
6	0 ^b	40 ^b	60 ^b	86 ^c	58 ^b	0 ^b	0 ^b	2.66 ^b	18.1 ^b	–1.0	+
7	90	100	100	87 ^c	25 ^b	32 ^b	33 ^b	2.29 ^b	4.4 ^b	1.5 ^b	–
8	78 ^b	100	100	84 ^c	71 ^b	72 ^b	0 ^b	0.91	7.1 ^b	4.0 ^b	+
9	58 ^b	40 ^b	100	72 ^b	71 ^b	36 ^b	0 ^b	2.53 ^b	–0.4	9.1 ^b	–
10	76 ^b	80 ^c	20 ^b	87 ^c	42 ^b	24 ^b	100	1.05	8.0 ^b	1.8 ^b	–
11	55 ^b	70 ^b	100	22 ^b	75 ^b	52 ^b	50 ^b	2.40 ^b	23.3 ^b	4.2 ^b	–
12	19 ^b	40 ^b	20	58 ^b	17 ^b	16 ^b	67 ^b	2.09 ^b	–0.4	5.7 ^b	+
13	67 ^b	60 ^b	20	89 ^c	8 ^b	16 ^b	0 ^b	3.30 ^b	12.4 ^{bb}	1.8 ^b	+
14	86	100	80 ^c	67 ^b	17 ^b	32 ^b	17 ^b	1.95 ^b	–0.4	1.9 ^b	+
15	55 ^b	50 ^b	100	25 ^b	25 ^b	0 ^b	0 ^b	2.47 ^b	6.6 ^b	0.5	+
16	37 ^b	50 ^b	20	0 ^b	92	60 ^b	17 ^b	2.19 ^b	–0.4	–0.2	–
17	36 ^b	20 ^b	0	3 ^b	0 ^b	0 ^b	0 ^b	1.01	10.5 ^b	–0.3	+
18	28 ^b	20 ^b	0	27 ^b	4 ^b	0 ^b	0 ^b	1.19	11.4 ^b	–0.1	+
19	62 ^b	60 ^b	60	81 ^c	83 ^b	52 ^b	67 ^b	2.61	–0.4	–1.0	–

Abbreviations: CCT = Camel and Cactus Test; comp = comprehension; MAST = Make A Sentence Test; SECT = Sentence Comprehension Test.

^a Chosen as indicated in the recommendation article.

^b Values outside 95% of the control group mean (z-scores >1.96).

^c Values indicate 1.5 < z-score < 1.96.

these variables are classically associated with the syndrome of semantic dementia, indicating that a semantic variant of PPA is readily identifiable. The second factor, which was only slightly less significant than the semantic factor, clustered grammatical comprehension, sentence repetition, apraxia of speech, grammatical production, and mean length of utterance. This factor, therefore, appears to correspond to nvPPA. Note, however, that impaired sentence repetition aligned with this factor, whereas it has been proposed to be a cardinal feature of lvPPA.

A binary rating of apraxia of speech was included in the analysis because it was listed as one of the key features in the recent classification article.⁵ It should be noted, however, that the definition of apraxia of speech remains a thorny issue because, at present, quantifiable measures for this feature are lacking. In this study, apraxia of speech was judged by 2 raters, blind to neuropsychological and clinical information, listening for “effortful halting speech with inconsistent speech sound errors and distortions”⁵ in recordings of connected speech and long word repetition.

Although overall interrater agreement was fairly high (93%), this was in large part because it was easy to decide on the absence of apraxia of speech in many of the patients. Making a positive diagnosis of apraxia of speech was more challenging. To date, the literature has largely defined apraxia of speech by clinical opinion, often citing that the rating was made by an expert.^{17–20} Without tangible criteria, however, this approach raises the question of whether one expert means the same thing as another. This problem is exemplified by the lack of agreement in how different groups have defined apraxia of speech.^{21–25} Moreover, even if interrater reliability between experts could be demonstrated, this may not be especially useful in cognitive neurology clinics in which such expertise will be variable. The present results suggest that, until validated measures are available, it might be better to abandon apraxia of speech as a classifying feature in PPA, given that the principle axis factoring strongly aligned this feature to agrammatism. Furthermore, removing apraxia of speech had no im-

Figure Scree plot showing the relative significance of different factors

Note the significant reduction in eigenvalue from factor 2 to factor 3.

pect on the clustering of the remaining markers in the factor matrix (table e-3).

After the semantic and agrammatic factors, there was a marked step down in significance for the remaining factors although 2 met the significance criterion of an eigenvalue ≥ 1 . The third axis included a number of connected speech measures comprising speech rate, frequency of complex grammatical structures, mean length of utterance (with a higher factor loading compared to the second axis), and frequency of hesitation markers. The fourth axis only included phonologic errors. As shown in the Scree plot (figure), the factors did not suggest evidence for a third discrete syndrome that stood out from the group. Furthermore, consistent with the application of clinical recommendations, which identified only 2 patients as meeting the proposed criteria for lvPPA, factors 3 and 4 did not resemble the description of logopenic aphasia. The proposed core features of lvPPA are impaired word retrieval (perhaps manifested by increased hesitation, i.e., word-finding pauses) and impaired sentence repetition, but these 2 features did not cluster together, with hesitations located in the third axis, whereas impaired sentence repetition aligned, with markers of agrammatism/apraxia of speech, to the second factor. It is also noteworthy that, although the criteria for lvPPA merely specify impaired sentence repetition with no further qualifications, we did not penalize apraxic errors in our sentence repetition task and the scoring criteria were weighted toward detection of impairments in maintaining the structure and content of the sentence as opposed to word-level errors (see appendix e-1). Moreover, the authors of the recommendations noted that single word repetition can be spared in

lvPPA, implying that the ratio of sentence to single word repetition might be a more specific indicator. When we replaced sentence repetition with a ratio of sentence (of 6–8 syllables) to single 2-syllable word repetition to see whether this might tease out a logopenic type factor, this variable still aligned with the nvPPA factor (data not shown). The proposed lvPPA criteria also stipulate phonologic errors, but this feature appeared in the fourth axis in isolation.

Taken together, the results of this prospective data-driven study raise questions about the existence of lvPPA as a discrete linguistic syndrome. The results do identify 3 groups in the sense that a substantial proportion of patients have neither the semantic nor the nonfluent/agrammatic variant. One can define a group by its absence of the features of other groups, but to call this a syndrome would not make sense. The 3 positive features proposed in lvPPA, impaired word retrieval, impaired sentence repetition, and phonologic errors, may simply be insufficiently specific to separate this group from the other 2 syndromes. This is not an unprecedented finding because a lack of specific and distinctive features in the logopenic group has previously been documented in the literature.²⁶ The remaining criteria for lvPPA were all negatives: absence of 1) impairment in word/object comprehension, 2) apraxia of speech, and 3) agrammatism. In other words, to some degree, implicit in the recommendations themselves is the notion that this syndrome is defined by the absence of the characteristics of the other 2 syndromes.

Previous studies have reported that, of the 3 syndromic variants, lvPPA is most associated with Alzheimer pathology^{27,28} although pathologic homogeneity cannot be viewed as evidence for a discrete clinical syndrome. Only 2 patients (4%) met the criteria for lvPPA in this consecutive cohort, yet previous studies have suggested that Alzheimer pathology is the underlying diagnosis in almost one-third of patients with PPA.^{29,30} Mixed PPA, in contrast, accounted for about one-third of cases in this cohort. We speculate that unlike the 2 reasonably discrete syndromes of semantic and nonfluent/agrammatic PPA, which are mainly associated with non-Alzheimer disease pathology,^{31,32} the linguistically heterogeneous features in these patients (mixed PPA) are most likely to be those associated with Alzheimer pathology.

Based on the present results, we propose that there are 2 clearly definable PPA syndromes: semantic and nonfluent/agrammatic. There are, in addition, a substantial number of patients with PPA who are not accommodated in these 2 syndromes. Such patients are heterogeneous in terms of language features. If one adopts a priori a tripartite view of PPA, as was recently proposed, then 3 groups will emerge,

but in this scenario, one syndrome will be defined as the absence of the other 2.

A caveat to the present findings is that this analysis was confined to the language features of the recently proposed recommendations; it is therefore at least possible that other linguistic markers may identify presently unknown language syndromes. In addition, on a methodologic note, we acknowledge that the number of participants in our study was relatively small compared with the number of language markers assessed. Conversely, the strength of the factor loadings, especially in the first 2 axes, which led to factor saturations greater than 0.6, argues for reliability of our findings: previous studies have suggested that strong factor loadings make the analysis less dependent upon the sample size.³³ Nevertheless, we acknowledge that this has been an exploratory analysis, and further studies are required to evaluate the findings of the present work.

AUTHOR CONTRIBUTIONS

Dr. Sajjadi: recruited patients, designed the neuropsychological test battery and developed one of the novel neuropsychological tests (sentence comprehension test [SECT]) under the supervision of Dr. Patterson and Dr. Nestor, collected part of the neuropsychological data, collected and analyzed the speech samples, carried out parts of the statistical analyses, prepared the first draft of Methods and Results sections, prepared the supplementary material, and finalized the manuscript in collaboration with Dr. Nestor and K. Patterson. K. Patterson: supervised Dr. Sajjadi in preparing the novel neuropsychological tests and analysis of speech samples, conceived the study in collaboration with Dr. Nestor and Dr. Sajjadi, revised and rewrote different parts of the manuscript. R.J. Arnold: collected a significant proportion of the neuropsychological data, collaborated in development of the novel neuropsychological tests. Dr. Watson: carried out major parts of the statistical analysis. Dr. Nestor: supervised Dr. Sajjadi in developing SECT, devised the make a sentence test (MAST) test, conceived the study in collaboration with Dr. Sajjadi and K. Patterson, first drafted introduction and discussion sections of the paper and revised and finalized the whole manuscript in collaboration with Dr. Sajjadi and K. Patterson.

DISCLOSURE

The authors report no disclosures relevant to the manuscript. **Go to Neurology.org for full disclosures.**

Received October 11, 2011. Accepted in final form January 23, 2012.

REFERENCES

- Mesulam MM. Primary progressive aphasia. *Ann Neurol* 2001;49:425–432.
- Grossman JM, Onishi K, Hughes E, et al. Progressive non-fluent aphasia: language, cognitive, and PET measures contrasted with probable Alzheimer's disease. *J Cogn Neurosci* 1996;8:135–154.
- Hodges JR, Patterson K, Oxbury S, Funnell E. Semantic dementia: progressive fluent aphasia with temporal lobe atrophy. *Brain* 1992;115:1783–1806.
- Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. *Ann Neurol* 2004;55:335–346.
- Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. *Neurology* 2011;76:1006–1014.
- Ash S, Moore P, Antani S, McCawley G, Work M, Grossman M. Trying to tell a tale: discourse impairments in progressive aphasia and frontotemporal dementia. *Neurology* 2006;66:1405–1413.
- Wilson SM, Henry ML, Besbris M, et al. Connected speech production in three variants of primary progressive aphasia. *Brain* 2010;133:2069–2088.
- Osher JE, Wicklund AH, Rademaker A, Johnson N, Weintraub S. The mini-mental state examination in behavioral variant frontotemporal dementia and primary progressive aphasia. *Am J Alzheimers Dis Other Dement* 2007;22:468–473.
- Grossman M, Xie SX, Libon DJ, et al. Longitudinal decline in autopsy-defined frontotemporal lobar degeneration. *Neurology* 2008;70:2036–2045.
- Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. *Int J Geriatr Psychiatry* 2006;21:1078–1085.
- Swinburn K, Porter G, Howard D. *Comprehensive Aphasia Test*. London: Psychology Press; 2004.
- Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol* 1999;56:303–308.
- Field A. *Discovering Statistics using SPSS*. London: Sage Publications; 2009.
- Mioshi E, Kipps CM, Dawson K, Mitchell J, Graham A, Hodges JR. Activities of daily living in frontotemporal dementia and Alzheimer disease. *Neurology* 2007;68:2077–2084.
- Xiong L, Xuereb JH, Spillantini MG, Patterson K, Hodges JR, Nestor PJ. Clinical comparison of progressive aphasia associated with Alzheimer versus FTD-spectrum pathology. *J Neurol Neurosurg Psychiatry* 2011;82:254–260.
- Mesulam M, Wieneke C, Rogalski E, Cobia D, Thompson C, Weintraub S. Quantitative template for subtyping primary progressive aphasia. *Arch Neurol* 2009;66:1545–1551.
- Josephs KA, Duffy JR, Strand EA, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. *Brain* 2006;129:1385–1398.
- Ogar JM, Dronkers NF, Brambati SM, Miller BL, Gorno-Tempini ML. Progressive nonfluent aphasia and its characteristic motor speech deficits. *Alzheimer Dis Assoc Disord* 2007;21:S23–S30.
- Ricci M, Magarelli M, Todino V, Bianchini A, Calandriello E, Tramutoli R. Progressive apraxia of speech presenting as isolated disorder of speech articulation and prosody: a case report. *Neurocase* 2008;14:162–168.
- Josephs KA, Duffy JR, Fossett TR, et al. Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants. *Arch Neurol* 2010;67:596–605.
- Croot K. Diagnosis of AOS: definition and criteria. *Semin Speech Lang* 2002;23:267–280.
- Kertesz A, Davidson W, McCabe P, Takagi K, Munoz D. Primary progressive aphasia: diagnosis, varieties, evolution. *J Int Neuropsychol Soc* 2003;9:710–719.
- Ogar J, Slama H, Dronkers N, Amici S, Gorno-Tempini ML. Apraxia of speech: an overview. *Neurocase* 2005;11:427–432.
- Rogalski E, Cobia D, Harrison TM, et al. Anatomy of language impairments in primary progressive aphasia. *J Neurosci* 2011;31:3344–3350.

25. Ash S, McMillan C, Gunawardena D, et al. Speech errors in progressive non-fluent aphasia. *Brain Lang* 2010;113:13–20.
26. Hu WT, McMillan C, Libon D, et al. Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. *Neurology* 2010;75:595–602.
27. Rabinovici GD, Jagust WJ, Furst AJ, et al. A β amyloid and glucose metabolism in three variants of primary progressive aphasia. *Ann Neurol* 2008;64:388–401.
28. Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. *Ann Neurol* 2008;63:709–719.
29. Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. *Brain* 2007;130:2636–2645.
30. Mesulam MM, Grossman M, Hillis A, Kertesz A, Weintraub S. The core and halo of primary progressive aphasia and semantic dementia. *Ann Neurol* 2003;54(suppl 5):S11–S14.
31. Snowden J, Neary D, Mann D. Frontotemporal lobar degeneration: clinical and pathological relationships. *Acta Neuropathol* 2007;114:31–38.
32. Hodges JR, Mitchell J, Dawson K, et al. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. *Brain* 2010;133:300–306.
33. Guadagnoli E, Velicer WF. Relation of sample size to the stability of component patterns. *Psychol Bull* 1988;103:265–275.

Editor's Note to Authors and Readers: Levels of Evidence coming to *Neurology*®

Effective January 15, 2009, authors submitting Articles or Clinical/Scientific Notes to *Neurology*® that report on clinical therapeutic studies must state the study type, the primary research question(s), and the classification of level of evidence assigned to each question based on the classification scheme requirements shown below (left). While the authors will initially assign a level of evidence, the final level will be adjudicated by an independent team prior to publication. Ultimately, these levels can be translated into classes of recommendations for clinical care, as shown below (right). For more information, please access the articles and the editorial on the use of classification of levels of evidence published in *Neurology*.¹⁻³

REFERENCES

1. French J, Gronseth G. Lost in a jungle of evidence: we need a compass. *Neurology* 2008;71:1634–1638.
2. Gronseth G, French J. Practice parameters and technology assessments: what they are, what they are not, and why you should care. *Neurology* 2008;71:1639–1643.
3. Gross RA, Johnston KC. Levels of evidence: taking *Neurology*® to the next level. *Neurology* 2009;72:8–10.

Classification scheme requirements for therapeutic questions

Class I. A randomized, controlled clinical trial of the intervention of interest with masked or objective outcome assessment, in a representative population. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.

Class II. A randomized, controlled clinical trial of the intervention of interest in a representative population with masked or objective outcome assessment that lacks one criterion a-e in Class I or a prospective matched cohort study with masked or objective outcome assessment in a representative population that meets b-e in Class I. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.

Class III. All other controlled trials (including well-defined natural history controls or patients serving as their own controls) in a representative population where outcome is independently assessed or independently derived by objective outcome measurements.

Class IV. Studies not meeting Class I, II, or III criteria including consensus or expert opinion.

AAN classification of recommendations

A = Established as effective, ineffective, or harmful (or established as useful/predictive or not useful/predictive) for the given condition in the specific population. (Level A rating requires at least two consistent Class I studies.)

B = Probably effective, ineffective, or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specific population. (Level B rating requires at least one Class I study or two consistent Class II studies.)

C = Possibly effective, ineffective, or harmful (or possibly useful/predictive or not useful/predictive) for the given condition in the specific population. (Level C rating requires at least one Class II study or two consistent Class III studies.)

U = Data inadequate or conflicting; given current knowledge, treatment (test, predictor) is unproven.